A Trial of Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in CD20+, B-cell Lymphomas, Gray Zone Lymphoma, and Hodgkin's Lymphoma
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Everolimus (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma; Hodgkin's disease; Lymphoma
- Focus Adverse reactions
- 07 Sep 2020 Status changed from active, no longer recruiting to completed.
- 11 Feb 2020 Planned End Date changed from 1 Nov 2019 to 1 Aug 2020.
- 21 Dec 2018 Planned End Date changed from 1 Jul 2020 to 1 Nov 2019.